At a glance
ClinicalIndex Comparison RecordN/ACompleted· 13 enrolled
Drug / intervention
iTind devicedevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Use of Temporarily Implanted Nitinol Device (iTind) System in Chinese Male Patients With Lower Urinary Tract Symptom Secondary to Benign Prostate Enlargement
In Brief
A clinical study evaluating iTind device for Prostate Hyperplasia. Completed, enrolled 13 participants across 1 site.
Detailed Summary
This is a prospective series of consecutive cases of patients undergoing iTind for the treatment of male LUTS.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProstate Hyperplasia
CountriesHong Kong
Collaborators--
Timeline
N/ACompletedFinished
2023202420252026
First PostedJul 2022
Enrollment StartSep 2022
Primary CompletionJan 2025
Study CompletionJan 2025
TodayJul 2026
First PostedJul 1, 2022
Enrollment StartSep 1, 2022
Primary CompletionJan 15, 2025
Study CompletionJan 21, 2025
TodayJul 1, 2026
Enrollment to primary: 2.4 yearsPosted 4 years ago
Interventions
iTind devicedevice
Cystoscopy will be performed to assess the anatomy of the bladder and prostate. The iTind device would be inserted under visual guidance into the bladder. The device will then be deployed and under visual guidance, it will be positioned at the prostatic lumen. After confirming the position of the device, cystoscopy will be withdrawn and the position will be finished.